 <h1>Mylocel Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>hydroxyurea</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about hydroxyurea. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Mylocel.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to hydroxyurea: oral capsule, oral tablet</i></p><h3>Warning</h3><p class="blackboxWarning-title">Oral route (Tablet)</p><p>Myelosuppression and MalignanciesMyelosuppression: Hydroxyurea oral tablets may cause severe myelosuppression. Monitor blood counts at baseline and throughout treatment. Interrupt treatment and reduce dose as necessary.Malignancies: Hydroxyurea is carcinogenic. Advise sun protection and monitor patients for malignancies.</p><p class="blackboxWarning-title">Oral route (Capsule)</p><p>Hydroxyurea may cause severe myelosuppression. Monitor blood counts at baseline and throughout treatment. Interrupt treatment and reduce dose as necessary. Hydroxyurea is carcinogenic. Advise sun protection and monitor patients for malignancy.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, hydroxyurea (the active ingredient contained in Mylocel) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking hydroxyurea:</p><p>
<i>More common</i>
</p><ul>
<li>Black, tarry stools</li>
<li>blood in the urine or stools</li>
<li>chills</li>
<li>cough</li>
<li>fever</li>
<li>hoarseness</li>
<li>lower back or side pain</li>
<li>painful or difficult urination</li>
<li>pale skin</li>
<li>pinpoint red spots on the skin</li>
<li>sore throat</li>
<li>ulcers, sores, or white spots in the mouth</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Blackening of the fingernails and toenails</li>
<li>troubled breathing with exertion</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Confusion</li>
<li>dizziness</li>
<li>headache</li>
<li>joint pain</li>
<li>seeing, hearing, or feeling things that are not there</li>
<li>seizures</li>
<li>swelling of the feet or lower legs</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Bleeding under the skin</li>
<li>blisters on the skin</li>
<li>bluish or pale color on the skin of the fingers or toes</li>
<li>coldness of the fingers or toes</li>
<li>crater-like lesions on the skin</li>
<li>drowsiness</li>
<li>fast heartbeat</li>
<li>hives, itching, skin rash</li>
<li>irritation</li>
<li>itching, pain, redness, or swelling on the leg</li>
<li>joint stiffness or swelling</li>
<li>loss of appetite</li>
<li>muscle spasms (tetany) or twitching seizures</li>
<li>nausea</li>
<li>numbness or tingling of the fingers or toes</li>
<li>pain in the fingers or toes</li>
<li>sore on the leg</li>
<li>swelling of the eyelids, face, lips, hands, or feet</li>
<li>tightness in the chest</li>
<li>trembling</li>
<li>troubled breathing or swallowing</li>
<li>vomiting</li>
<li>weight loss</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of hydroxyurea may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Diarrhea</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Constipation</li>
<li>redness of skin at the place of radiation</li>
<li>weight gain</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Absent, missed, or irregular menstrual periods</li>
<li>bluish-brownish bands on the nails</li>
<li>hair loss or thinning of hair</li>
<li>indigestion</li>
<li>passing of gas</li>
<li>stomach pain, fullness, or discomfort</li>
<li>stopping of menstrual bleeding</li>
</ul><p>
<!-- end oral capsule, oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to hydroxyurea: compounding powder, oral capsule, oral tablet</i></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Bone marrow failure, CD4 lymphocytes decreased, leukopenia, thrombocytopenia, platelet count decreased, anemia</p>
<p><b>Common</b> (1% to 10%): Neutropenia<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Pancreatitis, nausea, vomiting, diarrhea, stomatitis, constipation, mucositis, stomach discomfort, dyspepsia, abdominal pain, melena<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Pyrexia, asthenia, chills, malaise, fever, edema<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Cutaneous vasculitis, dermatomyositis, alopecia, maculopapular rash, papular rash, skin exfoliation, skin atrophy, skin ulcer, erythema, skin hyperpigmentation, nail disorder</p>
<p><b>Very rare</b> (less than 0.01%): Transverse melanonychia</p>
<p><b>Frequency not reported</b>: Squamous dysplasia, facial erythema<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Common</b> (1% to 10%): Skin cancers, neoplasms benign and malignant [including cysts and polyps])</p>
<p><b>Frequency not reported</b>: This drug has been shown to be mutagenic, clastogenic, and cause cellular transformation to a tumorigenic phenotype.  This drug has been reported to be unequivocally genotoxic and a presumed transspecies carcinogen, which implies a carcinogenic risk to humans.<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Azoospermia, oligospermia</p>
<p><b>Very rare</b> (less than 0.01%): Dysuria<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Convulsion, dizziness, peripheral neuropathy, drowsiness</p>
<p><b>Frequency not reported</b>: Severe peripheral neuropathy has been reported in HIV-infected patients who received this drug in combination with antiretroviral drugs<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Hepatotoxicity, hepatic enzyme increased, cholestasis, hepatitis</p>
<p><b>Frequency not reported</b>: Both fatal and nonfatal hepatotoxicity have been reported in HIV-infected patients who received this drug in combination with antiretroviral agents<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Pulmonary fibrosis, pulmonary edema, lung infiltration, dyspnea<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very rare</b> (less than 0.01%): Tumor lysis syndrome<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Hallucination, disorientation<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Dysuria, blood creatinine increased, blood urea increased, blood uric acid increased<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp."   ([2006]):</p><p id="ref_2">2. "Product Information. Droxia (hydroxyurea)." Bristol-Myers Squibb, Princeton, NJ. </p><p id="ref_3">3. "Product Information. Hydroxyurea (hydroxyurea (hydroxyUREA))." Par Pharmaceutical Inc, Chestnut Ridge, NY. </p><p id="ref_4">4. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p></div>
<div class="more-resources" id="moreResources">
<h2>More about Mylocel (hydroxyurea)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>Drug class: antimetabolites</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Hydrea, Droxia, Siklos</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Anemia, Sickle Cell</li>
<li>Solid Tumors</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to hydroxyurea: compounding powder, oral capsule, oral tablet</i></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Bone marrow failure, CD4 lymphocytes decreased, leukopenia, thrombocytopenia, platelet count decreased, anemia</p><p><b>Common</b> (1% to 10%): Neutropenia<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Pancreatitis, nausea, vomiting, diarrhea, stomatitis, constipation, mucositis, stomach discomfort, dyspepsia, abdominal pain, melena<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Pyrexia, asthenia, chills, malaise, fever, edema<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Cutaneous vasculitis, dermatomyositis, alopecia, maculopapular rash, papular rash, skin exfoliation, skin atrophy, skin ulcer, erythema, skin hyperpigmentation, nail disorder</p><p><b>Very rare</b> (less than 0.01%): Transverse melanonychia</p><p><b>Frequency not reported</b>: Squamous dysplasia, facial erythema<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Common</b> (1% to 10%): Skin cancers, neoplasms benign and malignant [including cysts and polyps])</p><p><b>Frequency not reported</b>: This drug has been shown to be mutagenic, clastogenic, and cause cellular transformation to a tumorigenic phenotype.  This drug has been reported to be unequivocally genotoxic and a presumed transspecies carcinogen, which implies a carcinogenic risk to humans.<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Azoospermia, oligospermia</p><p><b>Very rare</b> (less than 0.01%): Dysuria<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Convulsion, dizziness, peripheral neuropathy, drowsiness</p><p><b>Frequency not reported</b>: Severe peripheral neuropathy has been reported in HIV-infected patients who received this drug in combination with antiretroviral drugs<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Hepatotoxicity, hepatic enzyme increased, cholestasis, hepatitis</p><p><b>Frequency not reported</b>: Both fatal and nonfatal hepatotoxicity have been reported in HIV-infected patients who received this drug in combination with antiretroviral agents<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Pulmonary fibrosis, pulmonary edema, lung infiltration, dyspnea<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very rare</b> (less than 0.01%): Tumor lysis syndrome<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Hallucination, disorientation<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Dysuria, blood creatinine increased, blood urea increased, blood uric acid increased<sup>[Ref]</sup></p><p id="ref_1">1. Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp."   ([2006]):</p><p id="ref_2">2. "Product Information. Droxia (hydroxyurea)." Bristol-Myers Squibb, Princeton, NJ. </p><p id="ref_3">3. "Product Information. Hydroxyurea (hydroxyurea (hydroxyUREA))." Par Pharmaceutical Inc, Chestnut Ridge, NY. </p><p id="ref_4">4. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><h2>More about Mylocel (hydroxyurea)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>Drug class: antimetabolites</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Anemia, Sickle Cell</li>
<li>Solid Tumors</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>